RGS Stock Overview
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Regeneus Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.013 |
| 52 Week High | AU$0.02 |
| 52 Week Low | AU$0.003 |
| Beta | -0.26 |
| 11 Month Change | 116.67% |
| 3 Month Change | n/a |
| 1 Year Change | 8.33% |
| 33 Year Change | -90.00% |
| 5 Year Change | -87.62% |
| Change since IPO | -95.19% |
Recent News & Updates
Shareholder Returns
| RGS | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 160.0% | 0.4% | 0.5% |
| 1Y | 8.3% | 10.6% | 17.4% |
Return vs Industry: RGS underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: RGS underperformed the Australian Market which returned 9.6% over the past year.
Price Volatility
| RGS volatility | |
|---|---|
| RGS Average Weekly Movement | 32.4% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: RGS's share price has been volatile over the past 3 months.
Volatility Over Time: RGS's weekly volatility has decreased from 41% to 32% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Karolis Rosickas | regeneus.com.au |
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company’s platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing.
Regeneus Ltd Fundamentals Summary
| RGS fundamental statistics | |
|---|---|
| Market cap | AU$1.53m |
| Earnings (TTM) | -AU$366.01k |
| Revenue (TTM) | AU$988.43k |
4.0x
P/S Ratio-10.9x
P/E RatioIs RGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGS income statement (TTM) | |
|---|---|
| Revenue | AU$988.43k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$988.43k |
| Other Expenses | AU$1.35m |
| Earnings | -AU$366.01k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0012 |
| Gross Margin | 100.00% |
| Net Profit Margin | -37.03% |
| Debt/Equity Ratio | 0% |
How did RGS perform over the long term?
See historical performance and comparison